These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 30606076)

  • 21. Targeting HDACs for diffuse large B-cell lymphoma therapy.
    Wu C; Song Q; Gao S; Wu S
    Sci Rep; 2024 Jan; 14(1):289. PubMed ID: 38168914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diffuse large B-cell lymphoma with combined TP53 mutation and MIR34A methylation: Another "double hit" lymphoma with very poor outcome?
    Asmar F; Hother C; Kulosman G; Treppendahl MB; Nielsen HM; Ralfkiaer U; Pedersen A; Møller MB; Ralfkiaer E; de Nully Brown P; Grønbæk K
    Oncotarget; 2014 Apr; 5(7):1912-25. PubMed ID: 24722400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pathway activation in large B-cell non-Hodgkin lymphoma cell lines by doxorubicin reveals prognostic markers of in vivo response.
    Houldsworth J; Petlakh M; Olshen AB; Chaganti RS
    Leuk Lymphoma; 2008 Nov; 49(11):2170-80. PubMed ID: 19021061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PMA/IONO affects diffuse large B-cell lymphoma cell growth through upregulation of A20 expression.
    Yang W; Li Y; Li P; Wang L
    Oncol Rep; 2016 Aug; 36(2):1069-75. PubMed ID: 27349720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Frequency, spectrum, and functional significance of TP53 mutations in patients with diffuse large B-cell lymphoma].
    Voropaeva EN; Pospelova TI; Voevoda MI; Maksimov VN
    Mol Biol (Mosk); 2017; 51(1):64-72. PubMed ID: 28251968
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B-cell lymphoma.
    Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Meng B; Zhang H
    Hematol Oncol; 2019 Oct; 37(4):360-367. PubMed ID: 31359442
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD5-positive diffuse large B-cell lymphoma with an unusual phenotype: Cytoplasmic CD20 (+), surface CD20 (-).
    Yokose N; Shioi Y; Sugisaki Y; Ohaki Y; Ogata K; Dan K
    Leuk Lymphoma; 2006 Jul; 47(7):1415-7. PubMed ID: 16923582
    [No Abstract]   [Full Text] [Related]  

  • 30. miR-199a and miR-497 Are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients.
    Troppan K; Wenzl K; Pichler M; Pursche B; Schwarzenbacher D; Feichtinger J; Thallinger GG; Beham-Schmid C; Neumeister P; Deutsch A
    Int J Mol Sci; 2015 Aug; 16(8):18077-95. PubMed ID: 26251897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful treatment with lenalidomide plus chidamide combination therapy in 3 heavily treated patients with non-Hodgkin lymphoma: Three cases report.
    Hu S; Zou D; Zhou D; Zhang Y; Wang W; Zhang W
    Medicine (Baltimore); 2020 Oct; 99(43):e22788. PubMed ID: 33120793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma.
    Young KH; Weisenburger DD; Dave BJ; Smith L; Sanger W; Iqbal J; Campo E; Delabie J; Gascoyne RD; Ott G; Rimsza L; Müller-Hermelink HK; Jaffe ES; Rosenwald A; Staudt LM; Chan WC; Greiner TC
    Blood; 2007 Dec; 110(13):4396-405. PubMed ID: 17881637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic effect of chidamide on relapsed refractory angioimmunoblastic T-cell lymphoma: A case report and literature review.
    Jin J; Zheng C; Wu S
    Medicine (Baltimore); 2018 Jan; 97(2):e9611. PubMed ID: 29480865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
    Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
    Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Potential mechanism and prognostic value of promoter methylation of PRDM1 gene in diffuse large B cell lymphoma].
    Zhang XY; Ma ZP; Cui WL; Chen R; Glinaer A; Miao N; Li XX
    Zhonghua Bing Li Xue Za Zhi; 2016 Dec; 45(12):831-837. PubMed ID: 28056297
    [No Abstract]   [Full Text] [Related]  

  • 36. TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype.
    Zainuddin N; Berglund M; Wanders A; Ren ZP; Amini RM; Lindell M; Kanduri M; Roos G; Rosenquist R; Enblad G
    Leuk Res; 2009 Jan; 33(1):60-6. PubMed ID: 18706692
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].
    Iguchi T; Miyazawa K; Okabe S; Kawakubo K; Shimamoto T; Kuriyama Y; Ito Y; Kimura Y; Ohyashiki K; Serizawa H; Iwaya K; Mukai K
    Rinsho Ketsueki; 2004 Oct; 45(10):1129-34. PubMed ID: 15553050
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms.
    Du KX; Wu YF; Hua W; Duan ZW; Gao R; Liang JH; Li Y; Yin H; Wu JZ; Shen HR; Wang L; Shao Y; Li JY; Liang JH; Xu W
    Cell Commun Signal; 2024 Aug; 22(1):401. PubMed ID: 39148095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
    Ok CY; Xu-Monette ZY; Tzankov A; O'Malley DP; Montes-Moreno S; Visco C; Møller MB; Dybkaer K; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Han van Krieken J; Ponzoni M; Farnen JP; Piris MA; Winter JN; Medeiros LJ; Young KH
    Cancer; 2014 Jun; 120(12):1818-29. PubMed ID: 24648050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Composite diffuse large B-cell lymphoma and CD20-positive peripheral T-cell lymphoma.
    Yamazaki S; Fujioka Y; Nakamura F; Ota S; Shinozaki A; Yamamoto G; Kamikubo Y; Nannya Y; Ichikawa M; Fukayama M; Kurokawa M
    Pathol Int; 2011 Nov; 61(11):662-6. PubMed ID: 22029677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.